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Available online 28 January 2011Mobile thrombus in descending thoracic aorta in the
absence of aneurysm or atherosclerosis (non-aneurismal
non-atherosclerotic descending thoracic aorta or NAADTA)
is an uncommon finding with potential catastrophic conse-
quences due to the recognised likelihood of visceral and
peripheral embolisation.
In this issue of EJVES, Tsilimparis et al.1 contributed to
the understanding in this field by reporting on their expe-
rience with eight new cases of NAADTA, four managed by
conservative therapy (anticoagulation/anti-platelet) and
four by surgical/endovascular repair. Nevertheless, even
after this valuable update, few solutions and more queries
remain in a subject that is demanding to be managed and
still is largely unsettled.
The large ambiguity in management of NAADTA is
certainly due to the extreme rarity of the condition.
Whether this is explained by either under-diagnosis or true
low prevalence, or both, might be debated. Nevertheless,
even with the last imaging improvements (trans-oesopha-
geal echography, magnetic resonance, etc.) that have
increased the sensitivity in the detection of NAADTA in
recent years, the condition is today still very sporadically
observed. Tsilimparis et al.1 could find only eight NAADTA in
an overall experience alongside the last 12 years, and the
largest published series included only nine NAADTA cases.2
Tsilimparis et al. suggested to perform large screeningDOI of original article: 10.1016/j.ejvs.2010.11.004.
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doi:10.1016/j.ejvs.2010.11.016programs to thoroughly search NAADTA and the underlying
causes in many cases of supposed ‘cryptogenic’ embolism.1
Nevertheless, given the true low prevalence of NAADTA,
implementing depth screening in large populations might
be debatable and not cost effective as well.
Besides the numbers, the management of NAADTA is
challenging to standardise because of a ‘label’ inclusive of
different conditions: NAADTA does not represent a primary
disease but epiphenomenon and consequence of a number
of other underlying disorders, all combined under the same
identification mark. The literature review of Tsilimparis
et al. confirmed the large variety of aetiologies, mainly
malignancies and hyper-coagulable disorders, associated
with NAADTA.1 Given the highly heterogeneous field of
diseases, any uniform and standardised guidelines for
treatment are impractical.
Currently, long-term anticoagulation is the most widely
accepted first-line therapy in NAADTA. Surgical intervention is
reserved for patients with contraindications for or failing
conservative treatment. The efficacy of thrombus exclusion
with thoracic stent graft has recently been demonstrated in
limited published series. Although the superiority of each of
the three treatmentmodalities is yet tobedemonstrated, they
arenotmutuallyexclusive.More reliably, it is likely thatatriple
therapeutical approach can be necessary to best include the
threefold aspects of NAADTA: anticoagulation is mainly
required to treat the primary disease, endovascular repair to
exclude thoracic aortic thrombus and surgical thrombectomy
to solve peripheral/visceral ischaemic complications.
Even after successful surgical/endovascular treatment,
the need for long-lasting medical therapy is likely ind by Elsevier Ltd. All rights reserved.
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aspirin as a substitute for anticoagulation in three out of
eight patients who were at risk from bleeding. This valuable
medical alternative, already used by others,2 should be
substantiated by further studies also analysing the efficacy
of newer anti-platelet agents (as new-generation thieno-
pyridines) in NAADTA settings.
A final open issue of NAADTA concerns how to manage any
unrecognised thrombus occasionally detected in descending
aorta as a potential cause of cryptogenic embolism in the
future. This suggestion raises the question as to whether
the vulnerability/instability of thrombus and the causality
of thoracic thrombus leading to the development of ischae-
mic complications can be reliably recognised. The presenceof mural thrombus in an otherwise healthy thoracic aorta
(as in NAADTA) is certainly amarker of a disease; however, as
with carotid plaque, the mechanisms underlying diseases
with and without symptoms are far from being predicted.
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